论文部分内容阅读
目的:研究MAGE、BAGE、GAGE基因在子宫内膜癌组织及正常子宫内膜组织中的表达,并探讨其肿瘤特异性抗原作为子宫内膜癌免疫治疗特异性靶位的可能性。方法:采用逆转录-聚合酶联反应(RT-PCR)技术,检测35例子宫内膜癌组织和15例正常子宫内膜组织中MAGE-1、MAGE-3、BAGE和GAGE1-2基因的表达情况,以-βactin作内参照。结果:35例子宫内膜癌组织中,MAGE-1、MAGE-3、BAGE、GAGE1-2表达阳性率分别为46%(16/35)、49%(17/35)、20%(7/35)和26%(9/35),有77%的标本至少表达其中一种基因。15例正常子宫内膜组织中MAGE-1、MAGE-3、BAGE、GAGE1-2基因表达均为阴性。结论:肿瘤特异性抗原MAGE、BAGE、GAGE基因在子宫内膜癌中有较高的表达,MAGE-1、MAGE-3、BAGE基因的表达与子宫内膜癌的病理分期及分级无相关性,GAGE1-2与子宫内膜癌的分期无关,与分级有关。其可作为子宫内膜癌患者免疫治疗的特异性靶点。
OBJECTIVE: To study the expression of MAGE, BAGE and GAGE in endometrial carcinoma and normal endometrium, and to explore the possibility of using tumor-specific antigen as a specific target for endometrial cancer immunotherapy. Methods: The expressions of MAGE-1, MAGE-3, BAGE and GAGE1-2 in 35 cases of endometrial carcinoma and 15 cases of normal endometrium were detected by reverse transcription-polymerase chain reaction (RT-PCR) The situation, with -βactin as an internal reference. Results: The positive rates of MAGE-1, MAGE-3, BAGE and GAGE1-2 in 35 cases of endometrial carcinoma were 46% (16/35), 49% (17/35), 20% 35) and 26% (9/35), 77% of the specimens expressed at least one of the genes. The expression of MAGE-1, MAGE-3, BAGE and GAGE1-2 in 15 cases of normal endometrium were negative. CONCLUSIONS: MAGE, BAGE and GAGE gene of tumor-specific antigen are highly expressed in endometrial carcinoma. The expression of MAGE-1, MAGE-3 and BAGE has no correlation with the pathological stage and grade of endometrial carcinoma, GAGE1-2 has nothing to do with the stage of endometrial cancer, and grading. It can be used as a specific target of immunotherapy in patients with endometrial cancer.